Recently I caught up with one volunteer who recently received an experimental vaccine from Pfizer. 21-year-old Skyler Mener is a Junior at Kutztown University of Pennsylvania majoring in Social Work. In late August...
On the heels of Russia’s questionably early commencement of public production of the COVID-19 vaccine, leading SARS-CoV-2 vaccine manufacturers are quickly approaching the Thanksgiving vaccine moment.
In an annoucement today from Pfizer, the Government of Canada has entered into an agreement with the Pfizer and BioNTech to supply the partnership's BNT162 mRNA-based vaccine to combat COVID-19.
Today Pfizer and BioNTech have jointly announced they are prepared to begin their Phase II/III global trials for their COVID-19 vaccine partnership. Following on review of Phase I/II trial results, the partnership worked with the FDA to select BNT162b2 as the vaccine candidate in the next phases.
Pfizer and BioNTech biopharmaceutics announced today a $1.95 billion dollar agreement with the U.S. government for 100 million doses of the partnership's BNT162 program vaccine.
In a news release today, the BNT162b1 COVID-19 vaccine under development by Pfizer and BioNTech displayed early positive results in producing neutralizing antibodies from the partnership's Phase I/II trial.
As manufacturers worldwide race to develop the first viable COVID-19 vaccine faster than any vaccine ever developed in human history, late November remains an important date in the United States to vaccinate a large number of Americans.
The first vaccines for the COVID-19 pandemic may arrive in just shy of two months from today according to the World Health Organization (WHO) and several vaccine manufacturers.